Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.

This publication reviews the World Professional Association for Transgender Health's Standards of Care for supporting transgender and gender nonconforming people, with adjustments needed for diverse global contexts and no new clinical results.

This article discusses the heterogeneity of polycystic ovary syndrome, its association with insulin resistance, and its implications for long-term health, but reports no new clinical results.

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

This consensus report reviews current knowledge and identifies knowledge gaps concerning the various health aspects of polycystic ovary syndrome, without presenting new clinical findings.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

This review explores the cellular mechanisms of tissue repair and discusses how advancements in understanding wound pathology could lead to the development of more effective therapies for chronic, non-healing wounds, which are prevalent among individuals with diabetes and aging.

This review summarizes the cell type distribution and functional significance of human keratins, emphasizing their roles in tumor diagnosis and potential clinical applications, and reports no new clinical findings.

This review discusses the molecular role of the vitamin D receptor in regulating various biological actions such as bone mineralization and reports no new clinical results, highlighting the complexity of vitamin D's function in multiple tissues.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This review discusses the potential mechanisms by which androgens may elevate blood pressure, particularly through impacts on the renin-angiotensin system, but reports no new experimental results.

This review discusses the potential of single cell technologies to improve understanding and treatment of impaired wound healing and reports no new clinical results.

This review discusses the multiple severe side effects of cisplatin, carboplatin, and oxaliplatin in cancer treatment and reports no new clinical results; the authors emphasize the need for careful monitoring and supportive care to manage these effects.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This paper reviews the diagnostic criteria, associated morbidities, and possible evolutionary advantages of polycystic ovary syndrome, but does not report any new findings.

This article reviews the clinical features, diagnostic criteria, and possible genetic and environmental influences of polycystic ovary syndrome but provides no new research findings.

This article reviews the prevalence, risk factors, and clinical manifestations of polycystic ovary syndrome, highlighting current treatment and management options, but reports no new research findings.

In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.

This review emphasizes the need for comprehensive guidelines to address the cardiometabolic and psychological features of polycystic ovary syndrome, alongside its reproductive aspects, and reports no new results.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This review discusses the potential of platelet-rich plasma applications in regenerative medicine and explores recent progress and challenges in translating non-clinical PRP findings into human treatments, but reports no new clinical results.

Method detects finasteride in plasma at very low concentrations.

This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.

This review analyzes the reported prevalence of polycystic ovary syndrome (PCOS) based on different diagnostic criteria but does not provide new clinical results.

This study found that most patients hospitalized for COVID-19 experienced persistent symptoms over 100 days post-admission, with no significant difference in symptoms between those treated in regular wards and intensive care units.